Literature DB >> 10665657

Interaction of docetaxel ("Taxotere") with human P-glycoprotein.

K Shirakawa1, K Takara, Y Tanigawara, N Aoyama, M Kasuga, F Komada, T Sakaeda, K Okumura.   

Abstract

The interaction of docetaxel ("Taxotere") with P-glycoprotein (P-gp) was examined using porcine kidney epithelial LLC-PK1 and LLC-GA5-COL150 cells, overexpressing human P-gp selectively on the apical plasma membrane by transfection of human MDR1 cDNA into the LLC-PK1 cells. The basal-to-apical transport of [14C]docetaxel in LLC-GA5-COL150 cells significantly exceeded that in LLC-PK1 cells, but the apical-to-basal transport was decreased in LLC-GA5-COL150 cells. The intracellular accumulation after its basal or apical application to LLC-GA5-COL150 cells was 4- to 20-fold lower than that of LLC-PK1 cells. Multidrug resistance (MDR) modulators, i.e., cyclosporin A and SDZ PSC 833, inhibited the basal-to-apical transport and increased the apical-to-basal transport of [14C]docetaxel in LLC-GA5-COL150 cells, but verapamil affected only apical-to-basal transport. The intracellular accumulation after basal or apical application to LLC-GA5-COL150 cells was also increased by these three MDR modulators. These observations demonstrated that docetaxel is a substrate for human P-gp, suggesting that docetaxel-drug interactions occur via P-gp. The inhibition of [14C]docetaxel transport by the MDR modulators, as well as daunorubicin and vinblastine, was also found in LLC-PK1 cells, which endogenously express P-gp at lower levels, and concentrations showing similar levels of inhibition were lower than those in the case of LLC-GA5-COL150 cells. These observations indicate that it is necessary to consider the pharmacokinetic and pharmacodynamic interactions of docetaxel via P-gp.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10665657      PMCID: PMC5926029          DOI: 10.1111/j.1349-7006.1999.tb00723.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  30 in total

1.  Transepithelial transport of vinblastine by kidney-derived cell lines. Application of a new kinetic model to estimate in situ Km of the pump.

Authors:  M Horio; I Pastan; M M Gottesman; J S Handler
Journal:  Biochim Biophys Acta       Date:  1990-08-24

Review 2.  Biotransformation of taxoids by human cytochromes P450: structure-activity relationship.

Authors:  B Monsarrat; I Royer; M Wright; T Cresteil
Journal:  Bull Cancer       Date:  1997-02       Impact factor: 1.276

3.  Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs.

Authors:  K Takara; Y Tanigawara; F Komada; K Nishiguchi; T Sakaeda; K Okumura
Journal:  Biol Pharm Bull       Date:  1999-12       Impact factor: 2.233

Review 4.  Clinical pharmacokinetics of docetaxel.

Authors:  S J Clarke; L P Rivory
Journal:  Clin Pharmacokinet       Date:  1999-02       Impact factor: 6.447

Review 5.  Biochemical, genetic, and metabolic adaptations of tumor cells that express the typical multidrug-resistance phenotype. Reversion by new therapies.

Authors:  L G Baggetto
Journal:  J Bioenerg Biomembr       Date:  1997-08       Impact factor: 2.945

6.  Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans.

Authors:  F Marre; G J Sanderink; G de Sousa; C Gaillard; M Martinet; R Rahmani
Journal:  Cancer Res       Date:  1996-03-15       Impact factor: 12.701

7.  Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1).

Authors:  Y Tanigawara; N Okamura; M Hirai; M Yasuhara; K Ueda; N Kioka; T Komano; R Hori
Journal:  J Pharmacol Exp Ther       Date:  1992-11       Impact factor: 4.030

8.  Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro.

Authors:  B T Hill; R D Whelan; S A Shellard; S McClean; L K Hosking
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

9.  Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs.

Authors:  I Royer; B Monsarrat; M Sonnier; M Wright; T Cresteil
Journal:  Cancer Res       Date:  1996-01-01       Impact factor: 12.701

10.  Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein.

Authors:  N Kusunoki; K Takara; Y Tanigawara; A Yamauchi; K Ueda; F Komada; Y Ku; Y Kuroda; Y Saitoh; K Okumura
Journal:  Jpn J Cancer Res       Date:  1998-11
View more
  18 in total

1.  A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancers.

Authors:  Sanjay Goel; Kavita Desai; Manuel Macapinlac; Scott Wadler; Gary Goldberg; Abbie Fields; Mark Einstein; Fabio Volterra; Benny Wong; Russell Martin; Sridhar Mani
Journal:  Invest New Drugs       Date:  2006-03       Impact factor: 3.850

2.  Effects of prednisone on docetaxel pharmacokinetics in men with metastatic prostate cancer: A randomized drug-drug interaction study.

Authors:  Bodine P S Belderbos; Koen G A M Hussaarts; Leonie J van Harten; Esther Oomen-de Hoop; Peter de Bruijn; Paul Hamberg; Robbert J van Alphen; Brigitte C M Haberkorn; Martijn P Lolkema; Ronald de Wit; Robert J van Soest; Ron H J Mathijssen
Journal:  Br J Clin Pharmacol       Date:  2019-03-21       Impact factor: 4.335

Review 3.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

4.  Repurposing itraconazole as an anticancer agent.

Authors:  Hiroshi Tsubamoto; Tomoko Ueda; Kayo Inoue; Kazuko Sakata; Hiroaki Shibahara; Takashi Sonoda
Journal:  Oncol Lett       Date:  2017-06-07       Impact factor: 2.967

5.  Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4.

Authors:  M Katoh; M Nakajima; H Yamazaki; T Yokoi
Journal:  Pharm Res       Date:  2000-10       Impact factor: 4.200

6.  Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel.

Authors:  Hoai-Thu Thai; Florent Mazuir; Sylvaine Cartot-Cotton; Christine Veyrat-Follet
Journal:  Br J Clin Pharmacol       Date:  2015-08-14       Impact factor: 4.335

Review 7.  Novel insights into the organic solute transporter alpha/beta, OSTα/β: From the bench to the bedside.

Authors:  James J Beaudoin; Kim L R Brouwer; Melina M Malinen
Journal:  Pharmacol Ther       Date:  2020-04-02       Impact factor: 12.310

8.  Incorporation of ABCB1-mediated transport into a physiologically-based pharmacokinetic model of docetaxel in mice.

Authors:  Susan F Hudachek; Daniel L Gustafson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-04-25       Impact factor: 2.745

9.  ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel.

Authors:  Tristan M Sissung; Caitlin E Baum; John Deeken; Douglas K Price; Jeanny Aragon-Ching; Seth M Steinberg; William Dahut; Alex Sparreboom; William D Figg
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

Review 10.  ABC of oral bioavailability: transporters as gatekeepers in the gut.

Authors:  C G Dietrich; A Geier; R P J Oude Elferink
Journal:  Gut       Date:  2003-12       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.